Stock marker today: S&P 500 closes higher after Trump denies plans to fire Powell
Longevity Health Holdings Inc (NASDAQ:XAGE) experienced a dramatic premarket surge of 134.03% following the announcement of a transformative all-stock merger with THPlasma, a rapidly growing plasma collection company. The merger, valued at $59 million plus a $20 million earnout, represents a significant strategic pivot for the bio-aesthetics company into the lucrative plasma collection industry.
This acquisition follows Longevity’s previous acquisitions of Carmell Therapeutics in July 2023 and Elevai Skincare in January 2025, positioning the combined entity as a diversified player in the longevity and health sector.
Longevity Health Completes Strategic Merger with THPlasma
The merger between Longevity Health Holdings and THPlasma represents a strategic expansion into the plasma collection industry, addressing a critical shortage in the United States despite supplying over 60% of the world’s plasma.
THPlasma operates plasma collection centers in the Northeast United States with guaranteed sales offtake agreements worth up to $100 million annually. The company has demonstrated impressive growth, expanding from 2 centers in FY24 to 5 centers across New Jersey and Pennsylvania in FY25, while achieving cash profitability in FY2024.
THPlasma’s financial projections showcase robust growth potential, with estimated FY2025 revenue of $10 million and EBITDA of $2 million, scaling to projected FY2026 revenue of $32 million (220% year-over-year growth) and EBITDA of $7 million (250% growth).
The merger values THPlasma at 2.5 times FY26 estimated revenue inclusive of the earnout, while Longevity stock was valued at $3.00, representing a 12% premium to the July 11 closing price. Post-merger, George Chi will serve as Co-Chairman and CEO alongside Rajiv Shukla as Executive Chairman.
The transaction has received unanimous approval from both companies’ boards of directors and is expected to close in Q4 2025, subject to stockholder approvals and customary closing conditions. The merger also resulted in the mutual termination of Longevity’s previously announced 20/20 BioLabs transaction, indicating management’s confidence in the THPlasma opportunity as a superior strategic fit.
This dramatic increase reflects investor enthusiasm for the merger announcement and the strategic value creation potential of combining Longevity’s existing bio-aesthetics portfolio with THPlasma’s profitable plasma collection operations. The stock’s 52-week range of $2.00 to $48.60 indicates significant volatility, with the current surge representing a substantial recovery from recent lows.
The market response highlights investor confidence in the merger’s strategic rationale, particularly given THPlasma’s established profitability and guaranteed revenue streams through long-term offtake agreements.
With a current market capitalization of approximately $2.656 million and average daily volume of 512,232 shares, the premarket surge on volume of 22,149 shares suggests strong institutional and retail interest. The company’s beta of 0.56 indicates lower volatility relative to the broader market, though recent trading patterns suggest this may be evolving.
The merger positions the combined entity to capitalize on the growing plasma therapeutics market while maintaining Longevity’s existing focus on regenerative bio-aesthetics through its Carmell and Elevai platforms. Investors appear to be pricing in the synergistic potential between plasma-derived growth factors and the company’s existing therapeutic approaches, along with the immediate accretion from THPlasma’s profitable operations and growth trajectory.
***
Looking to start your trading day ahead of the curve? Get up to speed before the bell with Bull Whisper—a sharp, daily premarket newsletter packed with key news, market-moving updates, and actionable insights for traders.
Start your day with an edge. Subscribe to Bull Whisper using this link.